233 results on '"Kaplanski, G."'
Search Results
2. Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study
- Author
-
Widemann, A., Pasero, C., Arnaud, L., Poullin, P., Loundou, A.D., Choukroun, G., Sanderson, F., Lacroix, R., Sabatier, F., Coppo, P., Dignat‐George, F., and Kaplanski, G.
- Published
- 2014
- Full Text
- View/download PDF
3. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
- Author
-
Kyriazopoulou, E. Huet, T. Cavalli, G. Gori, A. Kyprianou, M. Pickkers, P. Eugen-Olsen, J. Clerici, M. Veas, F. Chatellier, G. Kaplanski, G. Netea, M.G. Pontali, E. Gattorno, M. Cauchois, R. Kooistra, E. Kox, M. Bandera, A. Beaussier, H. Mangioni, D. Dagna, L. van der Meer, J.W.M. Giamarellos-Bourboulis, E.J. Hayem, G. Netea, M.G. van der Meer, J.W.M. Giamarellos-Bourboulis, E.J. Volpi, S. Sormani, M.P. Signori, A. Bozzi, G. Minoia, F. Aliberti, S. Grasselli, G. Alagna, L. Lombardi, A. Ungaro, R. Agostoni, C. Blasi, F. Costantino, G. Fracanzani, A.L. Montano, N. Peyvandi, F. Sottocorno, M. Muscatello, A. Filocamo, G. Papadopoulos, A. Mouktaroudi, M. Karakike, E. Saridaki, M. Gkavogianni, T. Katrini, K. Vechlidis, N. Avgoustou, C. Chalvatzis, S. Marantos, T. Damoulari, C. Damoraki, G. Ktena, S. Tsilika, M. Koufargyris, P. Karageorgos, A. Droggiti, D.-I. Koliakou, A. Poulakou, G. Tsiakos, K. Myrodia, D.-M. Gravvani, A. Trontzas, I.P. Syrigos, K. Kalomenidis, I. Kranidioti, E. Panagopoulos, P. Petrakis, V. Metallidis, S. Loli, G. Tsachouridou, O. Dalekos, G.N. Gatselis, N. Stefos, A. Georgiadou, S. Lygoura, V. Milionis, H. Kosmidou, M. Papanikolaou, I.C. Akinosoglou, K. Giannitsioti, E. Chrysos, G. Mavroudis, P. Sidiropoulou, C. Adamis, G. Fragkou, A. Rapti, A. Alexiou, Z. Symbardi, S. Masgala, A. Kostaki, K. Kostis, E. Samarkos, M. Bakakos, P. Tzavara, V. Dimakou, K. Tzatzagou, G. Chini, M. Kotsis, V. Tsoukalas, G. Bliziotis, I. Doumas, M. Argyraki, A. Kainis, I. Fantoni, M. Cingolani, A. Angheben, A. Cardellino, C.S. Castelli, F. Serino, F.S. Nicastri, E. Ippolito, G. Bassetti, M. Selmi, C. International Collaborative Group for Anakinra in COVID-19
- Abstract
Background: Anakinra might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). We aimed to assess the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. Methods: For this systematic review and individual patient-level meta-analysis, a systematic literature search was done on Dec 28, 2020, in Medline (PubMed), Cochrane, medRxiv, bioRxiv, and the ClinicalTrials.gov databases for randomised trials, comparative studies, and observational studies of patients admitted to hospital with COVID-19, comparing administration of anakinra with standard of care, or placebo, or both. The search was repeated on Jan 22, 2021. Individual patient-level data were requested from investigators and corresponding authors of eligible studies; if individual patient-level data were not available, published data were extracted from the original reports. The primary endpoint was mortality after 28 days and the secondary endpoint was safety (eg, the risk of secondary infections). This study is registered on PROSPERO (CRD42020221491). Findings: 209 articles were identified, of which 178 full-text articles fulfilled screening criteria and were assessed. Aggregate data on 1185 patients from nine studies were analysed, and individual patient-level data on 895 patients were provided from six of these studies. Eight studies were observational and one was a randomised controlled trial. Most studies used historical controls. In the individual patient-level meta-analysis, after adjusting for age, comorbidities, baseline ratio of the arterial partial oxygen pressure divided by the fraction of inspired oxygen (PaO2/FiO2), C-reactive protein (CRP) concentrations, and lymphopenia, mortality was significantly lower in patients treated with anakinra (38 [11%] of 342) than in those receiving standard of care with or without placebo (137 [25%] of 553; adjusted odds ratio [OR] 0·32 [95% CI 0·20–0·51]). The mortality benefit was similar across subgroups regardless of comorbidities (ie, diabetes), ferritin concentrations, or the baseline PaO2/FiO2. In a subgroup analysis, anakinra was more effective in lowering mortality in patients with CRP concentrations higher than 100 mg/L (OR 0·28 [95% CI 0·17–0·47]). Anakinra showed a significant survival benefit when given without dexamethasone (OR 0·23 [95% CI 0·12–0·43]), but not with dexamethasone co-administration (0·72 [95% CI 0·37–1·41]). Anakinra was not associated with a significantly increased risk of secondary infections when compared with standard of care (OR 1·35 [95% CI 0·59–3·10]). Interpretation: Anakinra could be a safe, anti-inflammatory treatment option to reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially in the presence of signs of hyperinflammation such as CRP concentrations higher than 100 mg/L. Funding: Sobi. © 2021 Elsevier Ltd
- Published
- 2021
4. Diplorickettsia massiliensis as a human pathogen
- Author
-
Subramanian, G., Mediannikov, O., Angelakis, E., Socolovschi, C., Kaplanski, G., Martzolff, L., and Raoult, D.
- Published
- 2012
- Full Text
- View/download PDF
5. Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity
- Author
-
Chiche, L., Cournac, J.M., Mancini, J., Bardin, N., Thomas, G., Jean, R., Schleinitz, N., Kaplanski, G., Durand, J.M., Boucraut, J., and Harlé, J.R.
- Published
- 2011
- Full Text
- View/download PDF
6. Circulating endothelial cells and progenitors as prognosis factors during auto-immune thrombotic thrombocytopenic purpura: results of a prospective multicenter french study: VB10
- Author
-
Widemann, A, Pasero, C, Arnaud, L, Poullin, P, Loundou, A, Choukroun, G, Sanderson, F, Lacroix, R, Sabatier, F, Coppo, P, Dignat-George, F, and Kaplanski, G
- Published
- 2014
7. Rituximab as Preventive Therapy of a Clinical Relapse in TTP With ADAMTS13 Inhibitor
- Author
-
Schleinitz, N., Ebbo, M., Mazodier, K., Poullin, P., Bernit, E., Veit, V., Veyradier, A., Fakhouri, F., Kaplanski, G., and Harle, J. R.
- Published
- 2007
- Full Text
- View/download PDF
8. Accelerated hypertension and nephroangiosclerosis associated with antiphospholipid syndrome. Report of two cases and review of the literature
- Author
-
Durand, J. M., Lefevre, P., Kaplanski, G., Casanova, P., and Soubeyrand, J.
- Published
- 1994
- Full Text
- View/download PDF
9. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia
- Author
-
Chandesris, M.-O., Gayet, S., Schleinitz, N., Doudier, B., Harlé, J.-Robert, and Kaplanski, G.
- Published
- 2004
10. Increased soluble p55 and p75 tumour necrosis factor-α receptors in patients with hepatitis C-associated mixed cryoglobulinaemia
- Author
-
Kaplanski, G, Marin, V, Maisonobe, T, Sbai, A, Farnarier, C, Ghillani, P, Thirion, X, Durand, J. M, Harlé, J. R, Bongrand, P, Piette, J. C, and Cacoub, P
- Published
- 2002
11. Uveitis: From diagnosis to treatment [Uvéites : du diagnostic au traitement]
- Author
-
Saadoun, D., Trad, S., Bielfeld, P., Sene, D., Abad, S., Kaplanski, G., Terrada, C., Kodjikian, L., Bodaghi, B., Seve, P., Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de médecine interne [Avicenne], Hôpital Avicenne, Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Equipe 14, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
treatment planning ,uveitis ,diagnostic procedure ,Article ,[SPI.MAT]Engineering Sciences [physics]/Materials - Abstract
cited By 0; International audience
- Published
- 2018
12. Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel [Avis d'experts pour le traitement des uvéites non infectieuses]
- Author
-
Diwo, E., Sève, P., Trad, S., Bielefeld, P., Sène, D., Abad, S., Brézin, A., Quartier, P., Koné Paut, I., Weber, M., Chiquet, C., Errera, M.H., Sellam, J., Cacoub, P., Kaplanski, G., Kodjikian, L., Bodaghi, B., Saadoun, D., Equipe 14, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et maladies systémiques (SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de médecine interne [Avicenne], Hôpital Avicenne, CHU Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institute of Environmental Physics [Bremen] (IUP), University of Bremen, Service d'Ophtalmologie [Grenoble], Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [APHP], Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine (UMRS893), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)
- Subjects
treatment planning ,corticosteroid ,photometry ,clinical evaluation ,multimodal imaging ,laser flare photometry ,methotrexate ,[SPI.MAT]Engineering Sciences [physics]/Materials ,tocilizumab ,remission ,perimetry ,adalimumab ,human ,macular edema ,azathioprine ,rapamycin ,drug effect ,mycophenolate mofetil ,interferon ,drug indication ,cancer recurrence ,uveitis ,Short Survey ,electroretinography ,infliximab ,Behcet disease - Abstract
cited By 1; International audience; Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission. Interferon is an efficient immunomodulatory treatment, as a second-line therapy, for some therapeutic indications (refractory macular edema, Behçet's vascularitis). Other biologics, especially tocilizumab, are showing promising results. Local treatments (corticosteroids, sirolimus etc.) are adjuvant therapies in case of unilateral inflammatory relapse. Therapeutic response must be evaluated precisely by clinical examination and repeated complementary investigations (laser flare photometry, multimodal imaging, perimetry, electroretinography measures). © 2018 Société Nationale Française de Médecine Interne (SNFMI)
- Published
- 2018
13. Long-term results of therapy with interferon alpha for cryoglobulinemia associated with hepatitis C virus infection
- Author
-
Durand, J. M., Cretel, E., Kaplanski, G., Lefevre, P., Retornaz, F., and Soubeyrand, J.
- Published
- 1994
- Full Text
- View/download PDF
14. Foscarnet-induced hypercalcaema in AIDS
- Author
-
Gayet, S., Ville, E., Durand, J. M., Mars, M. E., Morange, S., Kaplanski, G., Gallais, H, and Soubeyrand, J.
- Published
- 1997
15. Antimony/interferon-γ combination in the treatment of visceral leishmaniasis in AIDS
- Author
-
Kaplanski, G., Buscaylet, S., Penot-Ragon, C., Durand, J-M., and Soubeyrand, J.
- Published
- 1996
16. Failure of atovaquone in the treatment of cerebral toxoplasmosis
- Author
-
Durand, J-M., Cretel, E, Bagneres, D., Guillemot, E., Kaplanski, G., and Soubeyrand, J.
- Published
- 1995
17. Erytrocyte CD59 reversible deficiency participates in cold agglutinin auto-immune hemolytic anemia pathogenesis
- Author
-
Brun, M, Cointe, S, Robert, S, Nicolino-Brunet, C, de Jaurreguiberry, Jp, Mazodier, K, Chandesris, Mp, Durand, Jm, Harlé, Jr, Chiaroni, J, Dignat-George, Francoise, Lacroix, R, Kaplanski, G, DIGNAT-GEORGE, Françoise, Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Physiopathologie de l'Endothelium, Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Laboratoire d'Immunologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)-Centre National de la Recherche Scientifique (CNRS), Médecine interne et immunologie clinique [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2016
18. Sjögren's syndrome and hepatitis C virus infection
- Author
-
Durand, J. M., Lefevre, P., Kaplanski, G., Retornaz, F., Cretel, E., Chaussegros, C., Trepo, C., and Soubeyrand, J.
- Published
- 1995
- Full Text
- View/download PDF
19. Pulmonary malignancy associated with granulomatous vasculitis in the maxillary sinus
- Author
-
Durand, J. M., Cretel, E., Kaplanski, G., and Soubeyrand, J.
- Published
- 1995
- Full Text
- View/download PDF
20. Lupus anticoagulant in silica-induced scleroderma
- Author
-
Durand, J. M., Aillaud, M. F., Kaplanski, G., Lefevre, P., Alessi, M. C., Juhan-Vague, I., and Soubeyrand, J.
- Published
- 1992
- Full Text
- View/download PDF
21. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
- Author
-
Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, and Durand JM
- Published
- 2012
22. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis.
- Author
-
Kaplanski, Gilles, Farnarier, Catherine, Payan, Marie-Josee, Bongrand, Pierre, Durand, Jean-Marc, Kaplanski, G, Farnarier, C, Payan, M J, Bongrand, P, and Durand, J M
- Abstract
Lymphocyte adhesion to endothelium, extravasation, and adhesion to hepatocytes are mediated by adhesion molecules and constitute important steps in the liver inflammation due to chronic hepatitis C (HCV-CH). We measured soluble intercellular adhesion molecule (sICAM-1, sCD54), vascular cell adhesion molecule (sVCAM-1, sCD106), E-selectin (sCD62E), as well as interleukin (IL)-1 beta, IL-8, and tumor necrosis factor-alpha (TNF-alpha) concentrations in the serum of 22 patients with HCV-CH in comparison to 20 seronegative healthy volunteers. sICAM-1, sVCAM-1, sCD62E, TNF-alpha, and IL-8 but not IL-1 beta concentrations were significantly elevated in patients. sICAM-1 and sCD62E correlated with TNF-alpha and aspartate amino transferases levels. sICAM-1 correlated with liver lobular inflammation whereas sVCAM-1, sCD62E, and IL-8 correlated with liver fibrosis. Measurement of soluble adhesion molecules may be an easy way to follow liver inflammation and fibrosis during HCV-CH. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
23. 'Nk-Like' T Cytotoxicity Against B Lymphocytes in a Hypogammaglobulinemic Patient.
- Author
-
Kaplanski, G., Seidel-Farnarier, C., Durand, J. M., Harl, J. R., Horchowski, N., Fossat, C., Bongrand, P., and Kaplanski, S.
- Published
- 1992
- Full Text
- View/download PDF
24. Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells.
- Author
-
Aiura, K, Clark, B D, Dinarello, C A, Margolis, N H, Kaplanski, G, Burke, J F, Tompkins, R G, and Gelfand, J A
- Abstract
The effect of activated platelets on cytokine production by human peripheral blood mononuclear cells (PBMC) was investigated. When PBMC were coincubated with activated autologous platelets amid lipopolysaccharide (LPS, 50-100 pg/mL) for 8 h, the production of interleukin (IL)-1alpha increased 11- to 18-fold and tumor necrosis factor (TNF)-alpha 3- to 5-fold compared with PBMC without platelets. Activated platelets in a dual-chamber well that prevented platelet-PBMC contact but permitted passage of soluble factors enhanced IL-1alpha production (P < .01). Platelet-PBMC contact in the chamber resulted in a further enhancement of IL-1alpha production. These data suggest that platelet-PBMC interaction, both directly and with platelet-derived factors, enhances production of shock-producing IL-1alpha and TNF-alpha, albeit differently. The interaction of platelets with monocytes may play an important role in the pathophysiology of sepsis and disseminated intravascular coagulation. [ABSTRACT FROM AUTHOR]
- Published
- 1997
25. Identical twins with macrophagic myofasciitis: Genetic susceptibility and triggering by aluminic vaccine adjuvants?
- Author
-
Guis, S., Mattei, J. P., Nicoli, F., Pellissier, J. F., Kaplanski, G., Figarella-Branger, D., Manez, G. C., Antipoff, G. M., and Roudier, J.
- Published
- 2002
- Full Text
- View/download PDF
26. Case report. Simultaneous occurrence of fibrillary glomerulopathy and AL amyloid.
- Author
-
Dussol, B, Kaplanski, G, Daniel, L, Brunet, P, Pellissier, J-F, and Berland, Y
- Abstract
Keywords:AL amyloidosis; fibrillary glomerulonephritis; IgM thrombi, Waldenstrom's macroglobulinaemia [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
27. Secondary pancreatic involvement of mycosis fungoides detected by a clinically palpable mass.
- Author
-
Kaplanski, G., Koeppel, M.C., Deharo, C., Durand, J.M., Andrac, L., and Sayag, J.
- Published
- 1994
- Full Text
- View/download PDF
28. Des taux élevés d'auto-anticorps anti-topo-isomérase-1 sont associés à l'extension de la fibrose cutanée et à la progression vasculaire chez les patients atteints de sclérodermie systémique.
- Author
-
Dol, C., Granel, B., Resseguier, N., Kaplanski, G., Reynaud-Gaubert, M., Schleinitz, N., Grob, J.-J., Delaporte, E., Lafforgue, P., Rossi, P., Bardin, N., and Benyamine, A.
- Subjects
- *
IMMUNOGLOBULINS , *DISEASE progression , *SEVERITY of illness index , *CARBON monoxide , *POLYMERASES - Abstract
La détection des auto-anticorps anti-centromères, anti-topo-isomérase-1 (ATA) et anti-ARN-polymérase III est utile pour déterminer le pronostic dans la sclérodermie systémique (ScS). Chez les patients positifs aux ATA, nous avons évalué si les taux d'ATA étaient associés à la gravité de la maladie au diagnostic et avec la progression au cours du suivi. Notre étude observationnelle rétrospective française monocentrique a été menée entre 2014 et 2021 chez les patients positifs pour les ATA, remplissant les critères de classification ACR/EULAR 2013 de la ScS, avec un suivi minimal d'un an et au moins 2 dosages d'ATA. Les patients ayant des ATA d'isotype IgG élevés à l'inclusion (> 240 UI/mL) ont été comparés aux patients présentant des taux faibles (≤ 240 UI/mL), à l'inclusion, à 1 et 3 ans. Une variation d'au moins 30 % des taux était considérée significative. Parmi les 59 patients inclus, ceux avec des taux élevés d'ATA présentaient une sclérose cutanée plus importante, évaluée par le score cutané de Rodnan modifié (p = 0,0480). Ils avaient un coefficient de transfert du monoxyde de carbone plus faible (p = 0,0457), une capacité vitale forcée plus faible (p = 0,0427). Des niveaux initiaux élevés d'ATA étaient associés à une progression vasculaire à un an (p = 0,0495). Les niveaux d'ATA semblent associés à la sclérose cutanée et la progression vasculaire dans la ScS. En plus de la simple détection des ATA, leur quantification pourrait être intéressante pour prédire la gravité et le pronostic de la ScS. Anti-centromere antibodies, anti-topoisomerase-1 antibodies (ATA), and anti-RNA-polymerase III antibodies are three Systemic Sclerosis (SSc)-specific autoantibodies. Their detection is helpful in determining the prognosis. We aimed to evaluate whether ATA levels were associated with disease severity at diagnosis or disease progression during follow-up in ATA positive patients. We conducted a single-centre French retrospective observational study, between 2014 and 2021. ATA positive patients fulfilling the ACR/EULAR 2013 classification criteria for SSc with a minimal follow-up of 1 year and 2 ATA dosages were included. SSc patients with high IgG ATA levels at baseline (> 240 IU/mL) were compared with SSc patients with low levels (≤ 240 IU/mL), at inclusion and at 1 and 3 years. A variation of at least 30 % of ATA levels was considered significant. Fifty-nine SSc patients were included and analysed. There was a predominance of women and of patients with diffuse interstitial lung disease. Patients with high ATA levels exhibited a higher skin sclerosis assessed by the modified Rodnan skin score (P = 0.0480). They had a lower carbon monoxide transfer coefficient (P = 0.0457), a lower forced vital capacity (FVC) (P = 0.0427) and more frequently had a FVC under 80 %, when compared to patients with low ATA levels (P = 0.0423). Initial high ATA levels were associated with vascular progression at one year (21.95 % vs. 0 %; P = 0.0495). ATA levels are associated with skin sclerosis and vascular progression in SSc. Beyond the detection of ATA, quantifying this autoantibody might be of interest in predicting disease severity and prognosis in SSc. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Liver failure due to recombinant alpha interferon.
- Author
-
Durand, J M, Kaplanski, G, Portal, I, Scheiner, C, Berland, Y, and Soubeyrand, J
- Published
- 1991
- Full Text
- View/download PDF
30. Cryoglobulinemia After Intravesical Administration of Bacille Calmette-Guérin.
- Author
-
Durand, J. M., Roubicek, C., Retornaz, F., Cretel, E., Payan, M. J., Bernard, J. P., Kaplanski, G., and Soubeyrand, J.
- Published
- 1998
31. Pleural Pseudotumoral Mass Revealing an Extrapulmonary Pneumocystis carinii Infection.
- Author
-
Kaplanski, G., Granel, B., Di Stefano, D., Durand, J. M., and Soubeyrand, J.
- Published
- 1996
- Full Text
- View/download PDF
32. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype.
- Author
-
Kaplanski, G, Retornaz, F, Durand, J, and Soubeyrand, J
- Published
- 1995
33. French recommendations for the management of non-infectious chronic uveitis.
- Author
-
Quartier, P., Saadoun, D., Belot, A., Errera, M.-H., Kaplanski, G., Kodjikian, L., Kone-Paut, I., Miceli-Richard, C., Monnet, D., Audouin-Pajot, C., Seve, P., Uettwiller, F., Weber, M., and Bodaghi, B.
- Subjects
- *
UVEITIS , *DISEASE management , *DISEASE relapse , *SPONDYLOARTHROPATHIES , *IMMUNOSUPPRESSIVE agents - Abstract
This French National Diagnostic and Care Protocol (NDPC) includes both pediatric and adult patients with non-infectious chronic uveitis (NICU) or non-infectious recurrent uveitis (NIRU). NICU is defined as uveitis that persists for at least 3 months or with frequent relapses occurring less than 3 months after cessation of treatment. NIRU is repeated episodes of uveitis separated by periods of inactivity of at least 3 months in the absence of treatment. Some of these NICU and NIRU are isolated. Others are associated with diseases that may affect various organs, such as uveitis associated with certain types of juvenile idiopathic arthritis, adult spondyloarthropathies or systemic diseases in children and adults such as Behçet's disease, granulomatoses or multiple sclerosis. The differential diagnoses of pseudo-uveitis, sometimes related to neoplasia, and uveitis of infectious origin are discussed, as well as the different forms of uveitis according to their main anatomical location (anterior, intermediate, posterior or panuveitis). We also describe the symptoms, known physiopathological mechanisms, useful complementary ophthalmological and extra-ophthalmological examinations, therapeutic management, monitoring and useful information on the risks associated with the disease or treatment. Finally, this protocol presents more general information on the care pathway, the professionals involved, patient associations, adaptations in the school or professional environment and other measures that may be implemented to manage the repercussions of these chronic diseases. Because local or systemic corticosteroids are usually necessary, these treatments and the risks associated with their prolonged use are the subject of particular attention and specific recommendations. The same information is provided for systemic immunomodulatory treatments, immunosuppressive drugs, sometimes including anti-TNFα antibodies or other biotherapies. Certain particularly important recommendations for patient management are highlighted in summary tables. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Hospitalisation pour infection chez les patients suivis pour une artérite à cellules géantes : étude monocentrique rétrospective.
- Author
-
Lavrard-Meyer, P., Gomes De Pinho, Q., Daumas, A., Benyamine, A., Ebbo, M., Schleinitz, N., Harlé, J.R., Jarrot, P.A., Kaplanski, G., Berbis, J., and Granel, B.
- Subjects
- *
COMORBIDITY , *GIANT cell arteritis , *HOSPITAL patients , *CORTICOSTEROIDS , *AGAMMAGLOBULINEMIA - Abstract
Les infections sont responsables de morbimortalité des patients souffrant d'artérite à cellules géantes (ACG). Le but de ce travail était double : l'identification de facteurs prédisposant au risque infectieux et la description des patients hospitalisés pour une infection survenant pendant la période de traitement de l'ACG. Nous avons mené une étude rétrospective monocentrique chez les patients ACG en comparant les patients hospitalisés pour infection avec des patients sans infection. L'analyse a porté sur 21/144 (14,6 %) patients ayant présenté 26 infections (cas), auxquels 42 témoins ont été appariés sur le sexe, l'âge et l'année du diagnostic d'ACG Les deux groupes étaient similaires en dehors d'une sérite au diagnostic plus fréquente chez les cas (15 % vs 0 %, p = 0,03). Les rechutes d'ACG étaient moins fréquentes chez les cas (23,8 % vs 50,0 %, p = 0,041). Une hypogammaglobulinémie était présente lors de l'infection. Plus de la moitié des infections (53,8 %) survenaient la première année du suivi sous une posologie moyenne de 15 mg/jour de prednisone. Les infections étaient surtout pulmonaires (46,2 %) et cutanées (26,9 %). Des facteurs associés au risque infectieux ont été identifiés. Ce travail préliminaire monocentrique va se poursuivre par une étude nationale multicentrique. Infections are associated with morbimortality of patients with giant cell arteritis (GCA). The aim of this work was twofold: the identification of factors predisposing to the risk of infection and the description of patients hospitalized with an infection occurring during the treatment period of CAG. A monocentric retrospective study was conducted in GCA patients, comparing patients hospitalized for infection with patients without infection. The analysis included 21/144 (14.6%) patients with 26 infections (cases) and 42 control matched on sex, age, and diagnosis of GCA. Both groups were similar except for a higher frequency of seritis in cases (15% vs. 0%, p = 0.03). Relapses of GCA were less common in cases (23.8% vs 50.0%, p = 0.041). Hypogammaglobulinemia was present during infection. More than half of the infections (53.8%) occurred in the first year of follow-up with an average dose of 15 mg/day of corticosteroids. Infections were mainly pulmonary (46.2%) and cutaneous (26.9%). Factors associated with infectious risk were identified. This preliminary monocentric work will continue with a national multicentre study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Leishmaniasis acquired in Belgium.
- Author
-
Kaplanski, G, Farnarier, C, Durand, J M, Soubeyrand, J, Bongrand, P, and Kaplanski, S
- Subjects
- *
LEISHMANIASIS , *MATERNAL-fetal exchange , *INFECTIOUS disease transmission - Published
- 1991
- Full Text
- View/download PDF
36. Dapsone Therapy for Thrombocytopenia in Patients Infected with Human Immunodeficiency Virus.
- Author
-
Durand, J. M., Lefevre, P., Cretel, E., Kaplanski, G., and Soubeyrand, J.
- Published
- 1996
- Full Text
- View/download PDF
37. Dysfonction endothéliale au cours du Purpura Thrombotique Thrombocytopénique : un nouvel axe de prise en charge ?
- Author
-
Prevel, R., Roubaud-Baudron, C., Tellier, E., Le Besnerais, M., Kaplanski, G., Veyradier, A., Benhamou, Y., and Coppo, P.
- Abstract
Le PTT auto-immun (PTTi) est une maladie rare presque constamment fatale en l'absence de traitement. Sa physiopathologie repose sur un déficit fonctionnel sévère de la métalloprotéase ADAMTS13 (activité < 10 %) secondaire à la présence d'auto-anticorps anti-ADAMTS13. L'âge est un facteur pronostique important pour la survie à court et long terme. Les patients atteints de PTTi âgés de 60 ans et plus, comparés aux patients plus jeunes, ont des atteintes d'organes plus fréquentes, en particulier cardiaques et rénales. Ils ont également une présentation neurologique moins spécifique (confusion, troubles du comportement, ...) entrainant un retard diagnostique. Les causes de la surmortalité dans cette population âgée sont mal connues et pourraient inclure l'altération de la réserve fonctionnelle des organes atteints, ainsi que le vieillissement cardio-vasculaire. Si le déficit sévère en ADAMTS13 est nécessaire à la survenue d'une poussée de PTTi, il n'est vraisemblablement pas suffisant. Un deuxième événement (modèle du « second coup ») de nature inflammatoire, entraine une activation endothéliale qui est un facteur précipitant primordial dans la physiopathologie du PTTi. Les mécanismes provoquant cette activation endothéliale semblent proches de ceux à l'œuvre au cours du vieillissement cardio-vasculaire. Il est donc possible que, lorsque cette activation endothéliale survient sur un endothélium sénescent, elle aboutisse plus fréquemment à une dysfonction endothéliale qui pourrait expliquer l'atteinte plus sévère chez les sujets âgés à la phase aiguë. En plus de ce rôle supposé à la phase aiguë, l'étude des causes de la surmortalité des patients âgés atteints de PTTi pourrait également permettre de confirmer si l'inflammation et la dysfonction endothéliale qui en découlent ont un impact sur le vieillissement cardio-vasculaire et la mortalité au décours. Cette implication confirmerait la nécessité de mieux comprendre le rôle de l'inflammation et de l'activation endothéliale, à la phase aiguë du PTTi et à plus long terme, car elles pourraient constituer de nouvelles cibles thérapeutiques. Immune Thrombotic Thrombocytopenic Purpura (iTTP) is a rare but severe disease with a mortality rate of almost 100 % in the absence of adequate treatment. iTTP is caused by a severe deficiency in ADAMTS13 activity due to the production of inhibitory antibodies. Age has been shown to be a major prognostic factor. iTTP patients in the elderly (60yo and over) have more frequent organ involvement, especially heart and kidney failures compared with younger patients. They also have non-specific neurologic symptoms leading to a delayed diagnosis. Factors influencing this impaired survival among older patients remain unknown so far. Alteration of the functional capacity of involved organs could be part of the explanation as could be the consequences of vascular aging. In fact, severe ADAMTS13 deficiency is necessary but likely not sufficient for iTTP physiopathology. A second hit leading to endothelial activation is thought to play a central role in iTTP. Interestingly, the mechanisms involved in endothelial activation may share common features with those involved in vascular aging, potentially leading to endothelial dysfunction. It could thus be interesting to better investigate the causes of mid- and long-term mortality among older iTTP patients to confirm whether inflammation and endothelial activation really impact vascular aging and long-term mortality in those patients, in addition to their presumed role at iTTP acute phase. If so, further insights into the mechanisms involved could lead to new therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Caractéristiques des patients de moins et de plus de 75 ans atteints d'artérite à cellules géantes : étude comparative de 164 patients.
- Author
-
Daumas, A., Bichon, A., Rioland, C., Benyamine, A., Berbis, J., Ebbo, M., Jarrot, P.-A., Gayet, S., Rossi, P., Schleinitz, N., Harle, J.-R., Kaplanski, G., Villani, P., and Granel, B.
- Subjects
- *
GIANT cell arteritis , *VASCULITIS treatment , *INFLAMMATION , *CARDIOVASCULAR diseases , *DISEASE complications - Abstract
Résumé Propos L'artérite à cellules géantes (ACG) est la plus fréquente des vascularites du sujet âgé. Afin d'évaluer l'impact de l'âge au diagnostic, nous avons comparé les caractéristiques des patients âgés de moins de 75 ans (< 75 ans) à celles des 75 ans et plus (≥ 75 ans). Patients et méthodes Nous présentons une étude rétrospective menée auprès de 164 patients ayant une ACG diagnostiquée entre 2005–2017. Tous les patients présentaient au moins 3/5 critères de l'ACR et avaient eu un angioscanner au diagnostic. L'âge moyen était de 73 ± 9,6 ans, 84 patients (59 femmes) étaient âgés de moins 75 ans, 80 patients (53 femmes) étaient âgés de 75 ans et plus. Résultats Les patients ≥ 75 ans avaient davantage d'antécédents cardiovasculaires (p = 0,026), d'hypertension artérielle (p = 0,005) et de complications ophtalmologiques (p = 0,02). Ils présentaient moins d'atteinte des gros troncs (p < 0,001), avaient une biologie moins inflammatoire et une histologie artérielle temporale plus fréquemment positive (p = 0,04). La dose initiale orale de cortisone ne différait pas entre les groupes. Il y avait davantage de bolus de méthylprednisolone prescrits chez les ≥ 75 ans (p = 0,01). La prescription d'un antiagrégant plaquettaire était similaire. Le taux de rechute, de corticodépendance et de sevrage en corticoïdes étaient comparables dans les deux groupes. Conclusion Dans cette étude, les sujets ≥ 75 ans au diagnostic avaient plus de complications ophtalmologiques et à l'inverse moins d'aortite scanographique. Il n'y avait pas de différence dans la prise en charge en dehors des bolus de corticoïdes plus fréquents chez les sujets ≥ 75 ans. Le profil évolutif n'était pas différent selon l'âge des patients au diagnostic. Abstract Purpose Giant cell arteritis (GCA) is the most common vasculitis of the elderly. In order to assess the impact of age at diagnosis, we compared the characteristics of patients of less than 75 years (< 75 years), to those of the 75 years and over (≥ 75 years). Patients and methods We conducted a retrospective study on 164 patients with GCA diagnosed from 2005 to 2017. All patients had at least 3/5 of the ACR criteria and had a CT-scan at diagnosis. The mean age was of 73 ± 9.6 years. The age was < 75 years for 84 patients (59 women) and ≥ 75 years for 80 patients (53 women). Results Patients ≥ 75 years had more cardiovascular underlying diseases (P = 0.026), a higher rate of hypertension (P = 0.005) and more ophthalmic complications (P = 0.02). They had less large vessel involvement (P < 0.001), showed lower biological inflammatory reaction and had a more frequently positive temporal artery histology (P = 0.04). The oral initial dose of corticosteroids did not differ between the groups. Corticosteroids pulse therapy was more frequent in patients ≥ 75 years (P = 0.01). The frequency of anti-platelet agents use was similar in the two groups. Relapse rate, corticodependance and the rate of corticosteroids weaning were similar in both groups. Conclusion Patients ≥ 75 years at diagnosis of GCA were at lower risk of aortitis but were more likely to suffer from ophthalmic complications and to receive corticosteroid pulse therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Thrombosis and recombinant interferon-alpha.
- Author
-
Durand, J M, Quiles, N, Kaplanski, G, and Soubeyrand, J
- Subjects
- *
INTERFERONS , *RECOMBINANT proteins , *VENOUS thrombosis , *VASCULITIS - Published
- 1993
- Full Text
- View/download PDF
40. Vincristine for thrombotic thrombocytopenic purpura.
- Author
-
Durand, J M, Lefevre, P, Kaplanski, G, Telle, H, and Soubeyrand, J
- Subjects
- *
THROMBOTIC thrombocytopenic purpura treatment , *PLASMA exchange (Therapeutics) , *VINCRISTINE - Published
- 1992
- Full Text
- View/download PDF
41. Patient-to-patient transmission of hepatitis C virus.
- Author
-
Durand, J, Lefevre, P, Kaplanski, G, and Soubeyrand, J
- Subjects
- *
HEPATITIS C transmission , *BLOODBORNE infections , *INFECTIOUS disease transmission , *CROSS infection , *HYPODERMIC needles , *PATHOGENIC microorganisms , *DISPOSABLE medical devices - Published
- 1995
- Full Text
- View/download PDF
42. Lepromatous leprosy and seropositivity for HTLV-I.
- Author
-
Harle, J R, Disdier, P, Kaplanski, G, Tamalet, C, Weiller-Merli, C, Bonerandi, J J, and Weiller, P J
- Subjects
- *
HANSEN'S disease , *RNA virus infections , *DISEASE complications - Published
- 1990
- Full Text
- View/download PDF
43. P 112 Beneficial effect of interferon alpha-2b in behçet's disease
- Author
-
Durand, J.M., Kaplanski, G., Telle, H., and Soubeyrand, J.
- Published
- 1993
- Full Text
- View/download PDF
44. Caractéristiques des patients sclérodermiques avec positivité des anticorps anti-Th/To.
- Author
-
Muller, R., Benyamine, A., Bertin, D., Harlé, J.R., Kaplanski, G., Mazodier, K., Raynaud-Gaubert, M., Rossi, P., Bardin, N., and Granel, B.
- Abstract
Les anticorps anti-Th/To font partie des nombreux anticorps associés à la sclérodermie, mais ils restent peu connus et peu étudiés. Le but de ce travail est de décrire les caractéristiques clinico-biologiques des patients sclérodermiques avec positivité des anticorps anti-Th/To. Nous avons collecté de manière rétrospective les caractéristiques clinico-biologiques de 6 patients positifs pour les anti-Th/To, identifiés à partir de la sérothèque du Laboratoire d'Immunologie de Marseille. Nous avons ensuite réalisé une méta-analyse de la littérature sur le sujet. Les 6 patients présentaient tous une sclérodermie systémique de forme cutanée limitée. Ils avaient un syndrome de Raynaud, des télangiectasies, un retentissement pulmonaire défini par une diminution de la DLCO, et des anticorps anti-nucléaires positifs d'aspect moucheté nucléolaire en immunofluorescence indirecte sur cellules HEp-2. Trois patients avaient également des anticorps anti-SSA, dont un seul avec un syndrome sec clinique associé. Notre revue de la littérature, incluant près de 8 727 patients sclérodermiques retrouve une fréquence moyenne des anticorps anti-Th/To de 3,4 % (0–14,3 %). Cette fréquence semble plus importante en Asie (4,7 %) qu'en Europe (1,5 %). Ces anticorps sont nettement associés à la forme cutanée limitée (87,5 %) de la maladie, et à l'atteinte pulmonaire pour environ 50 % des patients, bien que cette dernière soit définie de manière hétérogène selon les études (radiographie, scanner, EFR). La spécificité des anticorps anti-Th/To pour la sclérodermie est élevée, estimée entre 90 et 99 %, et leur positivité chez un patient est en général associée à la négativité des autres anticorps connus dans sclérodermie. Les données recueillies chez nos patients sont cohérentes avec celles de la littérature. La comparaison avec des patients sclérodermiques présentant des anti-centromères (anticorps les plus fréquemment associés à la forme cutanée limitée) suggère une plus forte fréquence de l'atteinte pulmonaire et un meilleur pronostic vasculaire en cas de positivité des anti-Th/To. Les anticorps anti-Th/To apparaissent donc être un marqueur non seulement diagnostique, mais aussi pronostique de la sclérodermie systémique. Du fait de leur grande spécificité, et de leur association à un profil phénotypique particulier (forme cutanée limitée et fréquence de l'atteinte fibrosante pulmonaire), les anticorps anti-Th/To revêtent un intérêt diagnostique et pronostique dans la sclérodermie systémique. Du fait de leur rareté et de leur caractère exclusif avec les autoanticorps classiques, leur recherche semble particulièrement pertinente en cas de suspicion de sclérodermie systémique avec négativité des anticorps conventionnels, en particulier en cas d'immunofluorescence nucléolaire moucheté des anticorps anti-nucléaires. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Comparaison des glucocorticoïdes plus rituximab versus glucocorticoïdes plus placebo dans le traitement des vascularites cryoglobulinémiques mixtes actives non infectieuses : résultats d'un essai randomisé contrôlé en double aveugle
- Author
-
Terrier, B., London, J., Bonnet, F., Cerruti, D., Costedoat-Chalumeau, N., Diot, E., Ferfar, Y., Hummel, A., Kaplanski, G., Marie, I., Quéméneur, T., Rullier, P., Senet, P., Le Gouellec, N., David, S., and Cacoub, P.
- Abstract
Une étude rétrospective antérieure a suggéré une supériorité des glucocorticoïdes (GC) plus rituximab (RTX) par rapport aux GC seuls pour induire une réponse clinique complète au cours des vascularites cryoglobulinémiques non infectieuses (VasCryo). Cependant, la combinaison de GC et RTX était associée à des infections sévères plus fréquentes, alors que le taux de mortalité ne différaient pas entre les schémas thérapeutiques. L'essai ESBAM (NCT02556866) visait à évaluer l'efficacité et la tolérance de RTX en association aux GC pour le traitement de VasCryo mixtes actives non infectieuses. Nous avons mené un essai multicentrique randomisé, en double aveugle, de supériorité du RTX par rapport au placebo pour l'induction de la rémission au cours des VasCryo mixtes actives non infectieuses. Pour être inclus, les patients devaient avoir un VasCryo active définie par une cryoglobuline sérique positive et une vascularite active, et devaient être des patients naïfs ou en rechute. Les patients étaient randomisés pour recevoir la prednisone plus le RTX administrée par perfusion intraveineuse à 375 mg/m2 aux jours (j) 1, 8, 15 et 22 ou la prednisone plus placebo administrée selon le même calendrier. Les GC étaient réduits progressivement de manière protocolaire. Le critère d'évaluation principal était la rémission de la VasCryo sans prednisone à la semaine (S) 24. Il était initialement prévu que cette étude inclut 79 patients par groupe. Entre juillet 2015 et juillet 2017, 15 patients ont été inclus dans l'essai ESBAM et 14 ont été randomisés (un patient est décédé avant la randomisation) : 5 pour recevoir RTX et 9 pour le groupe placebo. L'âge médian était de 62 ans [45 ; 71], 73 % étaient des femmes et 73 % étaient des patients en rechute. Les principales manifestations de la VasCryo incluaient : purpura (71 %), neuropathie (43 %), arthralgies (36 %) et glomérulonéphrite (29 %). Les caractéristiques des patients étaient comparables entre les groupes. À la semaine 24, 4/5 (80 %) avaient une vascularite inactive dans le groupe RTX contre 6/8 (75 %) dans le groupe placebo. Une rémission sans prednisone était obtenue chez 1/5 (20 %) dans le groupe RTX contre 0/8 dans le groupe placebo. Les doses cumulées de GC à S24 et à S48 étaient comparables entre les deux groupes. Au cours du suivi jusqu'à 48 semaines, 7 rechutes de vascularite sont survenues, 3 dans le groupe RTX et 4 dans le groupe placebo. Les taux de survie sans rechute à S48 étaient de 40,0 % [IC 13,7–100 %] dans le groupe RTX contre 41,7 % [IC 15,9–100 %] dans le groupe placebo. Le score de santé physique du SF-36 s'est significativement amélioré dans le groupe RTX par rapport au groupe placebo, en particulier à S36 et à S48 (p = 0,02 et p = 0,04, respectivement). La cryoglobulinémie est restée positive dans les deux groupes pour la majorité des patients, et l'évolution de la fraction C4 du complément était comparable entre les groupes au cours des 48 semaines. Vingt événements indésirables graves ont été enregistrés, dont une infection sévère patiente dans le groupe RTX et 2 dans le groupe placebo. Aucun patient n'est décédé après la randomisation. L'association de glucocorticoïdes plus rituximab, comparativement aux glucocorticoïdes plus placebo, semble induire des taux de rémission similaires à la 24e semaine au cours des VasCryo mixtes actives non infectieuses. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Vascular endothelial-cadherin is involved in endothelial cell detachment during thrombotic thrombocytopenic purpura.
- Author
-
Cauchois R, Lagarde M, Muller R, Faccini J, Leroyer A, Arnaud L, Poullin P, Dignat-George F, Kaplanski G, and Tellier E
- Subjects
- Humans, Animals, Phosphorylation, Male, Middle Aged, Female, Case-Control Studies, Adult, Calcium metabolism, Calcium blood, Endothelial Cells metabolism, ADAMTS13 Protein blood, ADAMTS13 Protein metabolism, Cells, Cultured, Mice, Mice, Inbred C57BL, Severity of Illness Index, Aged, Cadherins metabolism, Purpura, Thrombotic Thrombocytopenic blood, Human Umbilical Vein Endothelial Cells metabolism, Antigens, CD metabolism, Capillary Permeability, Cell Adhesion
- Abstract
Background: Immune thrombotic thrombocytopenic purpura (i-TTP) is a life-threatening thrombotic microangiopathy linked to ADAMTS-13 deficiency. It has long been assumed that the activation of endothelial cells is the triggering factor for the thrombotic thrombocytopenic purpura crisis. Circulating endothelial cells (CECs) have been shown to be a biomarker of vascular damage and are associated with the clinical severity of i-TTP. However, the mechanisms leading to endothelial cell detachment remain unclear., Objectives: We investigated junctional destabilization the mechanisms underlying cell detachment in thrombotic thrombocytopenic purpura., Methods: We quantified CECs in i-TTP patients and investigated the effect of plasmas in vitro by measuring phosphorylation and internalization of vascular endothelial (VE)-Cadherin and in vivo in a vascular permeability model., Results: In plasma from i-TTP patients, we show that CEC count is associated with severity and correlated to intracellular calcium influx (P < .01). In vitro, serum from i-TTP patients induced stronger detachment of human umbilical vein endothelial cells than serum from control patients (P < .001). Plasma from i-TTP patients induced a higher calcium-dependent phosphorylation (P < .05) and internalization (P < .05) of VE-cadherin compared with plasma from control patients. This effect could be reproduced by immunoglobulin (Ig)G fraction isolated from patient plasma and, in particular, by the F(ab)'2 fragments of the corresponding IgG. In addition, subcutaneous injection of i-TTP plasma into mice resulted in higher vascular permeability than plasma from control patients. An inhibitor of endothelial calcium influx, ITF1697, normalized this increase in permeability., Conclusion: Our results suggest that plasma-induced endothelial activation also leads to an increase in vascular permeability. They contribute to the understanding of the mechanisms behind the presence of elevated CECs in patients' blood by linking endothelial activation to endothelial injury., Competing Interests: Declaration of competing interests P.P. is a member of the scientific advisory boards of Ablynx-Sanofi. The other authors declare no competing financial interests., (Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Deciphering the Presentation and Etiologies of Hypophysitis Highlights the Need for Repeated Systematical Investigation.
- Author
-
Miquel L, Testud B, Albarel F, Sahakian N, Cuny T, Graillon T, Brue T, Dufour H, Schleinitz N, Kaplanski G, Ebbo M, and Castinetti F
- Abstract
Aims: Hypophysitis is defined as an inflammation of the pituitary gland and/or infundibulum. Our aim was to characterize the initial course and evolution of patients with hypophysitis according to the different etiologies., Patients and Methods: Retrospective observational study conducted in a universitary referral hospital center. Patients over 15 years of age were included if they had a diagnosis of hypophysitis between January 2014 and October 2023, with the exclusion of hypophysitis secondary to immune checkpoint inhibitors., Results: Sixty-one patients (64% women; median age, 34 years) were included. Polyuria-polydipsia, headache and asthenia were present in 64%, 48% and 44% of cases respectively. At diagnosis, at least one anterior pituitary deficiency was present in 91.5% of cases and vasopressin deficiency in 56%. MRI was abnormal in 97% of cases. Secondary hypophysitis was found in 46% of cases (n=28), including sarcoidosis in 28% (n=17) and L-group histiocytoses in 13.1% (n=8). Among patients with secondary hypophysitis, pituitary deficiency preceded systemic manifestations in 23% and occurred concomitantly in 23% of cases. Patients were treated in 36% of cases (glucocorticoids, surgery…), without improvement of pituitary hormone deficits., Conclusions: A systemic etiology of hypophysitis was found in almost half of the patients. Pituitary disorders preceded the systemic disease in a quarter of the cases. This emphasizes the importance of a systematic repeated workup looking for a secondary etiology of hypophysitis in these patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.)
- Published
- 2024
- Full Text
- View/download PDF
48. Tell-tale immune-related neurological syndromes: Should we look for and underlying low-grade B-cell lymphoma? A retrospective study on 12 cases.
- Author
-
Coen M, Benyamine A, Delmont E, Kaplanski G, Bouabdallah R, Xerri L, Attarian S, and Serratrice J
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Adult, Lymphoma, B-Cell pathology, Lymphoma, B-Cell immunology
- Abstract
Introduction: Immune-related neurological syndromes (affecting both the central and peripheral nervous system, as well as the neuromuscular junction) can associate with low-grade B-cell lymphomas., Methods: We conducted a retrospective study on the records of patients with miscellaneous immune-related neuropathies followed by the "Referral Centre for Neuromuscular Diseases and ALS" in collaboration with the Services of Internal Medicine and Hematology (La Timone Hospital, and the Paoli Calmettes-Insitute, Marseille, France; Geneva University Hospitals, Geneva, Switzerland). Clinical, biological, immunological and histological work-up was carried out and data collected., Results: We identified 12 patients with neurological syndromes and atypical presentation/course. In all these patients multiple autoantibodies were found. This prompted us to perform thorough hematologic investigations, that led to the diagnosis of different type of Low-Grade B-Cell lymphomas [i.e. marginal zone lymphomas with lymphoplasmacytic differentiation (n=3), splenic marginal area lymphoma with secondary lymph node invasion (n=1), unclassified marginal area lymphomas (n=8)]. Treatment of the underling lymphoma resulted in an improvement (n=8) or stabilization (n=4) of neurological disease., Conclusion: Atypical presentation of immune-related neurological syndromes, as well as the presence of antibodies with different antigenic targets should be regarded as "warning signs" and raise the suspicion of a paraneoplastic origin sustained by an underlying low-grade B-cell lymphoma that should be actively sought and treated. Close collaboration between internists, neurologists and hematologists allows for the appropriate management of each case., Competing Interests: Declaration of Competing Interest There is no conflict of interest., (Copyright © 2024. Published by Elsevier GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
49. Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.
- Author
-
Jarrot PA, Mirouse A, Ottaviani S, Cadiou S, Salmon JH, Liozon E, Parreau S, Michaud M, Terrier B, Gavand PE, Trefond L, Lavoiepierre V, Keraen J, Rekassa D, Bouldoires B, Weitten T, Roche D, Poulet A, Charpin C, Grobost V, Hermet M, Pallure M, Wackenheim C, Karkowski L, Grumet P, Rogier T, Belkefi N, Pestre V, Broquet E, Leurs A, Gautier S, Gras V, Gilet P, Holubar J, Sivova N, Schleinitz N, Durand JM, Castel B, Petrier A, Arcani R, Gramont B, Guilpain P, Lepidi H, Weiller PJ, Micallef J, Saadoun D, and Kaplanski G
- Subjects
- Adult, Humans, Middle Aged, COVID-19 Vaccines adverse effects, Ad26COVS1, BNT162 Vaccine, ChAdOx1 nCoV-19, Vaccination adverse effects, Giant Cell Arteritis epidemiology, Polymyalgia Rheumatica epidemiology, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines. We then conducted a nationwide survey to gather clinical profiles, therapeutic management, and follow-up data from individuals registered in the pharmacovigilance study. A total of 70 854 684 COVID-19 vaccine doses were administered to 25 260 485 adults, among which, 179 cases of PMR (RR 7. 1 cases/1 000 000 persons) and 54 cases of GCA (RR 2. 1 cases/1 000 000 persons) have been reported. The nationwide survey allowed the characterization of 60 PMR and 35 GCA cases. Median time to the onset of first symptoms was 10 (range 2-30) and 7 (range 2-25) days for PMR and GCA, respectively. Phenotype, GCA-related ischemic complications and -large vessel vasculitis as well as therapeutic management and follow-up seemed similar according to the number of vaccine shots received and when compared to the literature data of unvaccinated population. Although rare, the short time between immunization and the onset of first symptoms of PMR and GCA suggests a temporal association. Physician should be aware of this potential vaccine-related phenomenon.
- Published
- 2024
- Full Text
- View/download PDF
50. Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation.
- Author
-
Bonnez Q, Dekimpe C, Bekaert T, Tellier E, Kaplanski G, Joly BS, Veyradier A, Coppo P, Lammertyn J, Tersteeg C, De Meyer SF, and Vanhoorelbeke K
- Subjects
- Humans, Case-Control Studies, Biomarkers blood, Reproducibility of Results, Protein Conformation, Predictive Value of Tests, Immunoassay methods, Automation, Laboratory, Female, Male, ADAMTS13 Protein blood, ADAMTS13 Protein immunology, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic immunology, Surface Plasmon Resonance, Enzyme-Linked Immunosorbent Assay methods
- Abstract
Background: Laboratory diagnosis of immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains challenging when ADAMTS-13 activity ranges between 10% and 20%. To prevent misdiagnosis, open ADAMTS-13 conformation gained clinical attention as a novel biomarker, especially to diagnose acute iTTP in patients with diagnostic undecisive ADAMTS-13 activity. Plasma ADAMTS-13 conformation analysis corrects for ADAMTS-13 antigen, with both parameters being characterized in enzyme-linked immunosorbent assay (ELISA)-based reference assays requiring expert technicians., Objectives: To design ADAMTS-13 antigen and conformation assays on automated, easy-to-use fiber optic surface plasmon resonance (FO-SPR) technology to promote assay accessibility and diagnose challenging iTTP patients., Methods: ADAMTS-13 antigen and conformation assays were designed on FO-SPR technology. Plasma of 20 healthy donors and 20 acute iTTP patients were quantified, and data from FO-SPR and ELISA reference assays were compared., Results: Following assay design, both antigen and conformation FO-SPR assays were optimized and characterized, presenting strong analytical sensitivity (detection limit of 0.001 μg/mL) and repeatability (interassay variation of 14.4%). Comparative analysis suggested positive correlation (Spearman r of 0.92) and good agreement between FO-SPR and ELISA assays. As expected, FO-SPR assays showed a closed or open ADAMTS-13 conformation in healthy donors and acute iTTP patients, respectively., Conclusion: Both ADAMTS-13 antigen and conformation assays were transferred onto automated, easy-to-use FO-SPR technology, displaying potent analytical sensitivity and reproducibility. ADAMTS-13 antigen and conformation were determined for healthy donors and acute iTTP patients showing strong correlation with ELISA reference. Introducing FO-SPR technology in clinical context could support routine diagnosis of acute iTTP patients, notably when ADAMTS-13 activity fluctuates between 10% and 20%., Competing Interests: Declaration of competing interests J.L. is a member of the Board of Directors of FOx Biosystems. Q.B., C.D., T.B., E.T., G.K., B.S.J., A.V., P.C., C.T., S.F.D.M., and K.V. have no conflicts of interest to disclose., (Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.